-
Exclusive: Novan CEO Talks Strategic Partnerships, 2017 Pipeline, Finance Evaluation
Monday, March 27, 2017 - 2:29pm | 706Read More...2016 was a tumultuous year for biotech firms, but Novan Inc (NASDAQ: NOVN), which went public Sept. 21, thrived through the end of its lockup period on March 20. “In the past year, we were able to complete the IPO in extremely challenging market conditions and meaningfully increased our drug...
-
Novan CEO Talks About The Company's Future: 'Our Focus Is Put On SB204'
Friday, December 9, 2016 - 7:39pm | 617Read More...Benzinga recently had the chance to chat with Novan Inc (NASDAQ: NOVN)’s CEO Nathan Stasko. In a previous article, he talked about the company’s HPV drug; in this article, we’ll look into his prospects for the business, potential catalysts and financing. Capital Issues When...
-
Novan CEO Discusses Its HPV Drug And Clinical Trial Results
Friday, December 9, 2016 - 4:41pm | 585Read More...Novan Inc (NASDAQ: NOVN) is a small-cap late-stage pharmaceutical company focused on the treatment of acne vulgaris, external genital and perianal warts, fungal infections of the skin and nails, and inflammatory skin diseases. The stock has gained almost 58 percent since its late-September IPO,...
